Alessandro Rametta

Milan, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Local treatment of the primary tumour in mHSPC in the ARPI era: incremental value or overtreatment?

Local treatment of the primary tumour in mHSPC in the ARPI era: incremental value or overtreatment?

Journal: Expert review of anticancer therapy
Published: June 10, 2026

Lynch syndrome-associated urothelial carcinoma: clinical and molecular findings from a single-institution cohort.

Lynch syndrome-associated urothelial carcinoma: clinical and molecular findings from a single-institution cohort.

Journal: Familial cancer
Published: June 01, 2026

177Lu-PSMA-617 radioligand therapy as an immune modulator in prostate cancer.

177Lu-PSMA-617 radioligand therapy as an immune modulator in prostate cancer.

Journal: Expert review of anticancer therapy
Published: May 06, 2026

International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma.

International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma.

Journal: Tumori
Published: May 04, 2026

Predicting efficacy in patients with locally advanced/metastatic urothelial carcinoma (mUC) treated with immunotherapy using explainable machine learning approaches: the SamUR-AI trial on behalf of the Meet-URO group.

Predicting efficacy in patients with locally advanced/metastatic urothelial carcinoma (mUC) treated with immunotherapy using explainable machine learning approaches: the SamUR-AI trial on behalf of the Meet-URO group.

Journal: ESMO real world data and digital oncology
Published: April 03, 2026

Never Stop the Pressure: Maintaining Angiogenesis Inhibition Beyond Progression in Metastatic Renal Cell Carcinoma.

Never Stop the Pressure: Maintaining Angiogenesis Inhibition Beyond Progression in Metastatic Renal Cell Carcinoma.

Journal: JCO oncology practice
Published: March 31, 2026

Nectin-4 and Trop-2 expression in collecting duct carcinoma: new promising therapeutic targets.

Nectin-4 and Trop-2 expression in collecting duct carcinoma: new promising therapeutic targets.

Journal: ESMO open
Published: March 30, 2026

Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.

Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.

Journal: Frontiers in immunology
Published: February 26, 2026

The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study.

The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study.

Journal: The oncologist
Published: February 08, 2026

Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study.

Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study.

Journal: Clinical genitourinary cancer
Published: January 14, 2026

An update on the treatment paradigm for non-clear cell renal cell carcinoma.

An update on the treatment paradigm for non-clear cell renal cell carcinoma.

Journal: Expert review of clinical pharmacology
Published: January 10, 2026

Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25.

Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25.

Journal: Cancer immunology, immunotherapy : CII
Published: October 14, 2025
Showing 1-12 of 28

Last Updated: 09/26/2026